Literature DB >> 9618759

Loss- and gain-of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation.

A M Morrison1, S L Nutt, C Thévenin, A Rolink, M Busslinger.   

Abstract

Pax-5 codes for the transcription factor BSAP which is expressed throughout B cell development except in terminally differentiated plasma cells. Gene targeting experiments in the mouse revealed a differential dependency of fetal and adult B-lymphopoiesis on this transcription factor. BSAP is required for B-lineage commitment in the fetal liver and for progression beyond an early pro-B cell stage in adult bone marrow. The characterization of Pax-5-deficient pro-B cells demonstrated an important role of BSAP in the regulation of the CD19, mb-1 (Ig alpha) and N-myc genes as well as in the developmental pathway controlling VH-to-DHJH recombination at the immunoglobulin heavy-chain (IgH) locus. The human PAX-5 gene was recently shown to participate together with the IgH locus in the chromosomal translocation t(9;14)(p13;q32). This translocation is characteristic of a small subset of non-Hodgkin lymphomas exhibiting plasmacytoid differentiation. The translocated PAX-5 gene is deregulated by the insertion of IgH regulatory elements into its 5' region, which may contribute to tumorigenesis by interfering with the shut-down of PAX-5 transcription and thus with the completion of plasma cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618759     DOI: 10.1006/smim.1998.0115

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  12 in total

1.  BSAP can repress enhancer activity by targeting PU.1 function.

Authors:  S Maitra; M Atchison
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease.

Authors:  E Torlakovic; A Tierens; H D Dang; J Delabie
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 3.  A developing picture of lymphopoiesis in bone marrow.

Authors:  Jun Hirose; Taku Kouro; Hideya Igarashi; Takafumi Yokota; Nobuo Sakaguchi; Paul W Kincade
Journal:  Immunol Rev       Date:  2002-11       Impact factor: 12.988

4.  Vitamin A and immune function: retinoic acid modulates population dynamics in antigen receptor and CD38-stimulated splenic B cells.

Authors:  Qiuyan Chen; A Catharine Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-10       Impact factor: 11.205

5.  Expression of essential B cell development genes in horses with common variable immunodeficiency.

Authors:  R L Tallmadge; K A Such; K C Miller; M B Matychak; M J B Felippe
Journal:  Mol Immunol       Date:  2012-03-30       Impact factor: 4.407

Review 6.  Best Practice No 185. Cytological and molecular diagnosis of lymphoma.

Authors:  G Kocjan
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

7.  Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease.

Authors:  Daniela Capello; Gianluca Gaidano
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

8.  B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.

Authors:  Naoto Imoto; Fumihiko Hayakawa; Shingo Kurahashi; Takanobu Morishita; Yuki Kojima; Takahiko Yasuda; Keiki Sugimoto; Shinobu Tsuzuki; Tomoki Naoe; Hitoshi Kiyoi
Journal:  J Biol Chem       Date:  2015-12-24       Impact factor: 5.157

9.  A Network Model to Describe the Terminal Differentiation of B Cells.

Authors:  Akram Méndez; Luis Mendoza
Journal:  PLoS Comput Biol       Date:  2016-01-11       Impact factor: 4.475

10.  Early function of Pax5 (BSAP) before the pre-B cell receptor stage of B lymphopoiesis.

Authors:  C Thévenin; S L Nutt; M Busslinger
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.